Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2021 1
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
Cueva JF, Palacio I, Churruca C, Herrero A, Pardo B, Constenla M, Santaballa A, Manso L, Estévez P, Maximiano C, Legerén M, Marquina G, de Juan A, Quindós M, Sánchez L, Barquin A, Fernández I, Martín C, Juárez A, Martín T, García Y, Yubero A, Gallego A, Martínez Bueno A, Guerra E, González-Martín A. Cueva JF, et al. Among authors: barquin a. Eur J Cancer. 2023 Mar;182:3-14. doi: 10.1016/j.ejca.2022.12.023. Epub 2022 Dec 29. Eur J Cancer. 2023. PMID: 36706655
Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program.
Yubero A, Estévez P, Barquín A, Sánchez L, Santaballa A, Pajares B, Reche P, Salvador C, Manso L, Márquez R, González-Martín A. Yubero A, et al. Among authors: barquin a. Gynecol Oncol Rep. 2023 May 24;48:101211. doi: 10.1016/j.gore.2023.101211. eCollection 2023 Aug. Gynecol Oncol Rep. 2023. PMID: 37396679 Free PMC article.
Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.
Garcia-Donas J, Martínez-Urbistondo D, Velázquez Kennedy K, Villares P, Barquin A, Dominguez A, Rodriguez-Moreno JF, Caro E, Suarez Del Villar R, Nistal-Villan E, Yagüe M, Ortiz M, Barba M, Ruiz-Llorente S, Quiralte M, Zanin M, Rodríguez C, Navarro P, Berraondo P, Madurga R. Garcia-Donas J, et al. Among authors: barquin a. Front Immunol. 2023 Apr 18;14:1156603. doi: 10.3389/fimmu.2023.1156603. eCollection 2023. Front Immunol. 2023. PMID: 37143685 Free PMC article. Clinical Trial.
MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer.
Fenor MD, Ruiz-Llorente S, Rodríguez-Moreno JF, Caleiras E, Torrego JC, Sevillano-Fernández E, Navarro P, Yagüe-Fernández M, Amarilla-Quintana S, Barquín A, García-Donas J. Fenor MD, et al. Among authors: barquin a. Clin Transl Oncol. 2022 Dec;24(12):2432-2440. doi: 10.1007/s12094-022-02916-6. Epub 2022 Aug 22. Clin Transl Oncol. 2022. PMID: 35994225
Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
Yubero A, Barquín A, Estévez P, Pajares B, Sánchez L, Reche P, Alarcón J, Calzas J, Gaba L, Fuentes J, Santaballa A, Salvador C, Manso L, Herrero A, Taus Á, Márquez R, Madani J, Merino M, Marquina G, Casado V, Constenla M, Gutiérrez M, Dosil A, González-Martín A. Yubero A, et al. Among authors: barquin a. BMC Cancer. 2022 Nov 8;22(1):1150. doi: 10.1186/s12885-022-10191-5. BMC Cancer. 2022. PMID: 36348385 Free PMC article.
Proteomic profiles of peritoneal-derived small extracellular vesicles correlate with outcome in ovarian cancer patients.
Quiralte M, Barquín A, Yagüe Fernández M, Navarro P, Grazioso TP, Sevillano E, Rodriguez Moreno JF, Balarezo-Saldivar A, Peinado H, Izquierdo E, Millán C, López Carrasco I, Prieto M, Madurga de Lacalle R, Fernández-Miranda I, Ruiz-Llorente S, García-Donas J. Quiralte M, et al. Among authors: barquin a. J Clin Invest. 2024 Apr 2:e176161. doi: 10.1172/JCI176161. Online ahead of print. J Clin Invest. 2024. PMID: 38564289 Free article.